SI-BONE (SIBN) Expected to Announce Earnings on Monday

SI-BONE (NASDAQ:SIBN) is expected to post its quarterly earnings results after the market closes on Monday, February 24th. Analysts expect SI-BONE to post earnings of ($0.16) per share and revenue of $48.87 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

SI-BONE Price Performance

Shares of SI-BONE stock opened at $17.84 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The business’s 50 day simple moving average is $15.65 and its two-hundred day simple moving average is $14.66. The stock has a market capitalization of $748.21 million, a P/E ratio of -19.39 and a beta of 1.17. SI-BONE has a one year low of $11.70 and a one year high of $20.74.

Insider Transactions at SI-BONE

In related news, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the sale, the insider now directly owns 222,814 shares in the company, valued at $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the sale, the chief financial officer now owns 189,319 shares in the company, valued at $2,633,427.29. This represents a 2.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,311 shares of company stock worth $130,356. 3.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a research note on Monday, January 13th. Truist Financial lifted their price target on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.